[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 14 of about 14
1. Mosqueda Taylor A, Meneses García A, Ruíz Godoy Rivera LM, Suárez Roa Mde L, Luna Ortiz K: Malignant odontogenic tumors. A retrospective and collaborative study of seven cases. Med Oral; 2003 Mar-Apr;8(2):110-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant odontogenic tumors. A retrospective and collaborative study of seven cases.
  • The frequency, clinico-pathologic features and outcome of malignant odontogenic tumors diagnosed according to the current WHO classification in three pathology services in Mexico City are presented.
  • There were seven cases (5 male and 2 female patients), which represent less than 4% of all odontogenic tumors diagnosed in these services.
  • There were six odontogenic carcinomas (two malignant ameloblastomas, two clear cell odontogenic carcinomas, one primary intraosseous carcinoma and one carcinoma arising in an odontogenic cyst) and one ameloblastic fibrosarcoma.
  • Clear cell odontogenic carcinomas occurred in the canine-premolar region, one in the maxilla and one in the mandible (one ia a man and one in a woman), while the remaining lesions affected the posterior region of the mandible, with a male predominance (4:1), which agrees with previously reported cases.
  • Surgical resection was the treatment employed in all carcinomas, while the ameloblastic fibrosarcoma was treated with chemotherapy due to its large extension, but without favorable response.
  • The patient with primary intraosseous carcinoma had submaxillary and cervical metastases and the neoplasm was the cause of death.
  • In spite of their extremely low frequency, malignant odontogenic tumors are an important cause of extensive surgical procedures in the oral and maxillofacial region.
  • [MeSH-major] Odontogenic Tumors / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Ameloblastoma / pathology. Female. Humans. Male. Mandibular Neoplasms / pathology. Middle Aged. Odontogenic Cysts / pathology. Prospective Studies. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12618671.001).
  • [ISSN] 1137-2834
  • [Journal-full-title] Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal
  • [ISO-abbreviation] Med Oral
  • [Language] eng; spa
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Spain
  •  go-up   go-down


2. Gosau M, Baumhoer D, Ihrler S, Kleinheinz J, Driemel O: Ewing sarcoma of the mandible mimicking an odontogenic abscess - a case report. Head Face Med; 2008;4:24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing sarcoma of the mandible mimicking an odontogenic abscess - a case report.
  • We present a 24-year old male patient which underwent radical tumour surgery and primary reconstruction with a microvascular osteoseptocutaneous free fibular flap as well as postoperative adjuvant chemotherapy.
  • Incomplete osseous tumour resection required a second intervention.
  • This case report recapitulates the clinical and histopathological findings in oral ES, demonstrates its sometimes difficult diagnosis and discusses the (dis-)advantages of primary osseous reconstruction in ablative tumour surgery.
  • [MeSH-major] Abscess / diagnosis. Mandibular Diseases / diagnosis. Mandibular Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Facial Asymmetry / diagnosis. Humans. Male. Mouth Neoplasms / pathology. Neoplasm Invasiveness. Osteolysis / diagnosis. Tongue Neoplasms / pathology. Young Adult

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Abscess.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sao Paulo Med J. 2000 Nov 9;118(6):198-200 [11120553.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Oct;61(10):1216-9 [14586861.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Mar;62(3):335-43 [15015167.001]
  • [Cites] J Craniofac Surg. 2005 Nov;16(6):1140-6 [16327573.001]
  • [Cites] Oncologist. 2006 May;11(5):503-19 [16720851.001]
  • [Cites] J Oral Sci. 2007 Jun;49(2):167-71 [17634731.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Sep;36(9):802-6 [17614257.001]
  • [Cites] Head Neck. 2008 Mar;30(3):405-10 [17657795.001]
  • [Cites] Mund Kiefer Gesichtschir. 2007 Nov;11(5):251-7 [18376426.001]
  • (PMID = 18983686.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2644679
  •  go-up   go-down


3. Ram H, Mohammad S, Husain N, Gupta PN: Ameloblastic carcinoma. J Maxillofac Oral Surg; 2010 Dec;9(4):415-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic carcinoma (AC) is a rare aggressive malignant epithelial odontogenic tumor of the maxillofacial skeleton with a distinct predilection in the mandible.
  • It may appear de novo or originate from a pre-existing ameloblastoma or odontogenic cyst.
  • It may present as a cystic lesion with benign clinical features or as a large tissue mass with ulceration, significant bone resorption and tooth mobility.
  • Direct extension of the tumour, lymph node involvement and metastasis to various sites has been reported.
  • Wide local excision is the treatment of choice.
  • Radiotherapy and chemotherapy have limited role in the treatment of ameloblastic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22190836.001).
  • [ISSN] 0974-942X
  • [Journal-full-title] Journal of maxillofacial and oral surgery
  • [ISO-abbreviation] J Maxillofac Oral Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3177477
  • [Keywords] NOTNLM ; Ameloblastic carcinoma / Ameloblastoma / Odontogenic tumor
  •  go-up   go-down


Advertisement
4. Kawano K, Ono K, Yada N, Takahashi Y, Kashima K, Yokoyama S, Yanagisawa S: Malignant calcifying epithelial odontogenic tumor of the mandible: report of a case with pulmonary metastasis showing remarkable response to platinum derivatives. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jul;104(1):76-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant calcifying epithelial odontogenic tumor of the mandible: report of a case with pulmonary metastasis showing remarkable response to platinum derivatives.
  • We describe a case of CEOT of the mandible, which underwent malignant transformation and developed metastatic tumors of the lung after repeated local recurrence.
  • The primary tumor revealed typical histological features of benign CEOT showing sheets of polyhedral epithelial cells associated with abundant eosinophilic amyloid-like materials.
  • On the other hand, the locally recurrent tumors had malignant features, such as increased nuclear pleomorphism with frequent mitotic figures and vascular invasion of tumor cells, as well as increased proliferative activity assessed by immunostaining for Ki-67.
  • Chemotherapy was carried out against the pulmonary metastatic lesions, which showed a drastic response after 3 courses of intravenous administration of cisplatin (CDDP).
  • To date, a total of 6 courses of CDDP and 6 courses of nedaplatin (CDGP) have been done, and the remaining pulmonary tumors have been dormant.
  • This suggests that platinum derivatives could be a chemotherapeutic agent of choice against this rare tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Lung Neoplasms / drug therapy. Mandibular Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Odontogenic Cyst, Calcifying / drug therapy
  • [MeSH-minor] Bone Transplantation. Humans. Male. Mandible / radiography. Mandible / surgery. Middle Aged. Organoplatinum Compounds / therapeutic use

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577547.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Zhang L, Zeng D, Huang H, Wang J, Tao Q, Pan C, Xu J, Zhang B, Wang A: Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model. J Oral Pathol Med; 2010 Jan;39(1):94-102
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of metalloproteinase-2 inhibits ameloblastoma growth in a new mouse xenograft disease model.
  • BACKGROUND: Ameloblastomas are odontogenic neoplasms characterized by local invasiveness.
  • This study was conducted to develop a new animal model of ameloblastoma and to address the role of tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 (MMP-2) in the growth and invasiveness of ameloblastomas.
  • METHOD: Donated fresh human ameloblastoma tissue was finely minced, screened, and subcutaneously implanted in three locations on each of 10 BALB/c-nu/nu nude mice.
  • Newly established tumors on each mouse were injected with: (i) transfection reagent;.
  • Tumors were monitored for 5 weeks and excised for histopathology, RNA, and protein analyses.
  • In addition, we demonstrated the successful introduction of the TIMP-2 gene in tumor xenograft cells in vivo, resulting in xenograft growth inhibition.
  • [MeSH-major] Ameloblastoma / drug therapy. Neoplasm Transplantation. Soft Tissue Neoplasms / drug therapy. Tissue Inhibitor of Metalloproteinase-2 / therapeutic use. Transplantation, Heterologous
  • [MeSH-minor] Adult. Animals. Blotting, Western. Disease Models, Animal. Female. Genetic Vectors / therapeutic use. Humans. Matrix Metalloproteinase 2. Matrix Metalloproteinase Inhibitors. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Plasmids / therapeutic use. Reverse Transcriptase Polymerase Chain Reaction. Subcutaneous Tissue / surgery. Transfection. Tumor Cells, Cultured

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19895658.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.24 / Mmp2 protein, mouse
  •  go-up   go-down


6. Gosau M, Draenert FG, Müller S, Frerich B, Bürgers R, Reichert TE, Driemel O: Two modifications in the treatment of keratocystic odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)--a retrospective study lasting between 2 and 10 years. Clin Oral Investig; 2010 Feb;14(1):27-34
Hazardous Substances Data Bank. CHLOROFORM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two modifications in the treatment of keratocystic odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)--a retrospective study lasting between 2 and 10 years.
  • This retrospective study aimed at evaluating the recurrence rates of keratocystic odontogenic tumors (KCOTs) that were enucleated with and without the application of Carnoy's solution (CS).
  • Recurrence rates were investigated in correlation with the respective treatment method applied.
  • Additionally, any damage to the inferior alveolar nerve associated with treatment was analyzed.
  • Treatments consisted of enucleation with (38.9%) or without (61.1%) the application of CS.
  • [MeSH-major] Acetic Acid / therapeutic use. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Chloroform / therapeutic use. Ethanol / therapeutic use. Jaw Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control. Odontogenic Tumors / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cautery / methods. Child. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Mandibular Nerve / drug effects. Middle Aged. Neovascularization, Pathologic / drug therapy. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Oral Investig. 2010 Dec;14(6):719-21 [20838833.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Jan;36(1):20-5 [17156974.001]
  • [Cites] J Oral Maxillofac Surg. 1985 Mar;43(3):177-82 [2579223.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):497-502 [9341860.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jun;52(6):599-606 [8189298.001]
  • [Cites] Br J Oral Maxillofac Surg. 1997 Feb;35(1):46-8 [9043004.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] J Can Dent Assoc. 2008 Mar;74(2):165-165h [18353202.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):553-8 [11077375.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Jun;62(6):651-5; discussion 655-6 [15170272.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Jan;50(1):22-6 [1370082.001]
  • [Cites] J Oral Maxillofac Surg. 2005 May;63(5):635-9 [15883937.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Sep;72(3):265-9 [1717918.001]
  • [Cites] Mund Kiefer Gesichtschir. 2007 Sep;11(4):221-31 [17641919.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):379-83 [16487797.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):960-3 [8064460.001]
  • [Cites] J Dent Res. 1999 Jul;78(7):1345-53 [10403462.001]
  • [Cites] Int J Oral Maxillofac Surg. 1988 Feb;17(1):25-8 [3127485.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1662-6 [16243184.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):964-6 [8064461.001]
  • [Cites] J Oral Sci. 2007 Sep;49(3):229-35 [17928730.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jan;101(1):5-9; discussion 10 [16360602.001]
  • [Cites] J Oral Maxillofac Surg. 2001 Jul;59(7):720-5; discussion 726-7 [11429726.001]
  • [Cites] Med Oral. 2001 Nov-Dec;6(5):350-7 [11694868.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Aug;94(2):151-6 [12221380.001]
  • [Cites] Dtsch Zahnarztl Z. 1991 Jan;46(1):80-3 [1725863.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Nov;94(5):543-53 [12424446.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Nov;86(5):573-7 [9830650.001]
  • [Cites] Oral Maxillofac Surg Clin North Am. 2003 Aug;15(3):317-24 [18088685.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):42-7 [9690244.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25 [11289615.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1990 Sep-Oct;14(5):375-7 [2135243.001]
  • [Cites] J Maxillofac Surg. 1981 Nov;9(4):228-36 [6172530.001]
  • [Cites] J Oral Maxillofac Surg. 1984 Jan;42(1):10-9 [6199488.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • (PMID = 19294436.001).
  • [ISSN] 1436-3771
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carnoy's solution; 3K9958V90M / Ethanol; 7V31YC746X / Chloroform; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


7. Vigneswaran N, Fernandes R, Rodu B, Baughman RA, Siegal GP: Aggressive osteoblastoma of the mandible closely simulating calcifying epithelial odontogenic tumor. Report of two cases with unusual histopathologic findings. Pathol Res Pract; 2001;197(8):569-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive osteoblastoma of the mandible closely simulating calcifying epithelial odontogenic tumor. Report of two cases with unusual histopathologic findings.
  • Aggressive osteoblastoma is a rare bone-forming neoplasm composed of prominent epithelioid cells that demonstrate locally invasive growth with a high rate of recurrence but no metastatic potential.
  • Both tumors were resected with wide surgical margins and neither patient had adjuvant radiation or chemotherapy.
  • These tumors were composed of solid sheets of pleomorphic epithelioid cells, eosinophilic amorphous osteoid with foci of calcification, which closely simulated amyloid.
  • Differentiation of this tumor from histologically similar calcifying epithelial odontogenic tumor and low-grade osteosarcoma proved difficult.
  • [MeSH-major] Ameloblastoma / pathology. Mandibular Neoplasms / pathology. Osteoblastoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Epithelioid Cells / pathology. Female. Humans. Immunohistochemistry. Male. Osteoblasts / pathology. Osteocalcin / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11518051.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin; 104982-03-8 / Osteocalcin
  •  go-up   go-down


8. Siddiqui S, Bruker CT, Kestler DP, Foster JS, Gray KD, Solomon A, Bell JL: Odontogenic ameloblast associated protein as a novel biomarker for human breast cancer. Am Surg; 2009 Sep;75(9):769-75; discussion 775
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Odontogenic ameloblast associated protein as a novel biomarker for human breast cancer.
  • Odontogenic Ameloblast Associated Protein (ODAM) is a protein isolated in ameloblasts during odontogenesis.
  • The purpose of this study is to determine if ODAM expression can serve as a prognostic marker and provide information regarding treatment in human breast cancer.
  • Breast cancer patients were identified from our tumor registry from 1993 to 2003.
  • Archived breast cancer tissue from 243 patients (stage 0 = 53, stage I = 51, stage II = 53, stage III = 47, stage IV = 39) was stained using monoclonal antibody for ODAM.
  • Presence or absence of immunostaining was correlated with stage, histologic grade, response to chemotherapy, and survival using chi2 and logistic regression analyses.
  • Tumor nuclear staining for ODAM increased with increasing group stage (P < 0.001).
  • Staining for ODAM did not correlate with histologic grade or chemotherapy (P = 0.558, P = 0.093).
  • Survival benefit associated with tumor nuclear staining increased with advancing stage (P < 0.001).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Carrier Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19774947.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / ODAM protein, human
  •  go-up   go-down


9. Ricard AS, Majoufre-Lefebvre C, Siberchicot F, Laurentjoye M: A multirecurrent ameloblastoma metastatic to the lung. Rev Stomatol Chir Maxillofac; 2010 Apr;111(2):98-100
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The ameloblastoma is a rare tumor of odontogenic epithelial origin.
  • It is a neoplasm in which ameloblastic features are revealed by the primary growth in jaws and by any metastatic growth.
  • The curative treatment is surgical.
  • The results of palliative chemotherapy and radiotherapy are not always efficient.
  • [MeSH-major] Ameloblastoma / pathology. Ameloblastoma / secondary. Lung Neoplasms / secondary. Mandibular Neoplasms / pathology. Mandibular Neoplasms / surgery
  • [MeSH-minor] Adult. Bone Transplantation. Humans. Lung / surgery. Male. Mandible / surgery. Neoplasm Recurrence, Local / surgery. Reconstructive Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20347463.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


10. Huguet P, Castellví J, Avila M, Alejo M, Autonell F, Basas C, Bescos MS: Ameloblastic fibrosarcoma: report of a case. Immunohistochemical study and review of the literature. Med Oral; 2001 May-Jul;6(3):173-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic fibrosarcoma is a rare malignant odontogenic tumour characterized by a benign epithelial component within a malignant fibrous stroma.
  • Its behaviour is relatively benign, with absence of metastatic disease, and the prognosis is reported to be good.
  • It is a paradoxical neoplasm with "sarcomatous" morphological and immunohistochemical patterns but with a favourable clinical course.
  • We report a new case of this tumour in a mandibular ramus of a 31-years-old male patient, that was surgically excised and treated with adjuvant chemotherapy and radiotherapy.
  • Five years later the patient is free of disease.
  • The growth potential of ameloblastic fibrosarcoma is evaluated and compared with a related lesion, the ameloblastic fibroma.
  • [MeSH-major] Mandibular Neoplasms / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Epithelial Cells / pathology. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Mesoderm / pathology. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Radiotherapy, Adjuvant. Tumor Suppressor Protein p53 / analysis

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11500634.001).
  • [ISSN] 1137-2834
  • [Journal-full-title] Medicina oral : órgano oficial de la Sociedad Española de Medicina Oral y de la Academia Iberoamericana de Patología y Medicina Bucal
  • [ISO-abbreviation] Med Oral
  • [Language] eng; spa
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 16
  •  go-up   go-down


11. Sauk JJ, Nikitakis NG, Scheper MA: Are we on the brink of nonsurgical treatment for ameloblastoma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Jul;110(1):68-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are we on the brink of nonsurgical treatment for ameloblastoma?
  • OBJECTIVE: Recent identification of altered molecular signaling pathways in neoplasia has begun to elucidate mechanisms of oncogenesis, differentiation, and tumor progression, and to suggest plausible nonsurgical considerations for treatment.
  • Here we review the sonic hedgehog (SHH) and PI3K/Akt/mTOR signaling pathways, their role in ameloblastoma, a locally aggressive odontogenic tumor, and evidence for consideration of therapeutic approaches that target these molecular pathways.
  • RESULTS: The expression of SHH signaling molecules in ameloblastomas at the mRNA and protein levels has intimated that these molecules may play a role in cell proliferation of these tumors.
  • Immunohistochemical analysis has revealed aberrant signaling in the PI3K/Akt/mTOR pathway in ameloblastomas and appears to be a valuable tool for elucidating pathogenesis and aggressiveness, and selecting optimal therapeutics.
  • CONCLUSION: The understanding of altered pathways in ameloblastoma may soon provide nonsurgical options for the treatment of this condition.
  • Thus, tumors that entirely depend on active SHH signaling for survival/growth and maintenance may well be susceptible targets for combined chemotherapy with SHH-specific inhibitors together with PI3K, Akt, or mTOR blocking agents.
  • [MeSH-major] Ameloblastoma / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Hedgehog Proteins / antagonists & inhibitors. Hedgehog Proteins / physiology. Humans. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Intracellular Signaling Peptides and Proteins / physiology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / physiology. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / physiology. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / physiology. TOR Serine-Threonine Kinases. Transcription Factors / antagonists & inhibitors. Transcription Factors / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20418126.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / SHH protein, human; 0 / Transcription Factors; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


12. Nakano H, Ota Y, Yura Y: Calcifying epithelial odontogenic tumor of the maxilla with ulcerative stomatitis: a case report. Br J Oral Maxillofac Surg; 2009 Apr;47(3):222-4
Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcifying epithelial odontogenic tumor of the maxilla with ulcerative stomatitis: a case report.
  • Calcifying epithelial odontogenic tumor (CEOT) is a rare benign odontogenic tumor, known as Pindborg tumor.
  • [MeSH-major] Gingivitis, Necrotizing Ulcerative / etiology. Maxillary Neoplasms / pathology. Odontogenic Tumors / pathology
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Calcinosis. Female. Humans. Mouth Mucosa / pathology. Mucositis / drug therapy. Mucositis / etiology. Mucositis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790551.001).
  • [ISSN] 1532-1940
  • [Journal-full-title] The British journal of oral & maxillofacial surgery
  • [ISO-abbreviation] Br J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


13. Abada RL, Kadiri F, Tawfik N, Benchakroun N, Bouchbika Z, Chekkoury AI, Benchakroun Y, Benider A: [Multiple metastases of a mandibular ameloblastoma]. Rev Stomatol Chir Maxillofac; 2005 Jun;106(3):177-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ameloblastoma is a benign odontogenic tumor which can be locally aggressive and invasive.
  • Metastases are rare but possible and must be considered as a malignant form of the tumor.
  • OBSERVATION: A 50-year-old woman presented a jugal metastasis of a mandibular ameloblastom which had been treated several times 28 years earlier.
  • Six months after resection of the metastasis, the patient developed multiple cervical node metastases which were removed by radical curettage.
  • Five months later, new metastases developed on the scalp and three months later a voluminous metastasis involving the right hemiface extended to the base of the skull.
  • DISCUSSION: The absence of any histological sign of malignity in the primary tumor and in the metastases, as observed in our patient, is remarkable.
  • The time to development of a metastasis is generally very long and metastases usually remain asymptomatic.
  • Progression is very slow, like for the primary tumor.
  • Several factors predictive of metastasis have been described: female gender, age at onset of primary tumor (2nd to 3rd decade) and multiple local recurrences.
  • There is no standard treatment for metastases.
  • Chemotherapy is not effective.
  • Surgical resection remains the treatment of choice.
  • [MeSH-major] Ameloblastoma / secondary. Mandibular Neoplasms / pathology
  • [MeSH-minor] Female. Follow-Up Studies. Head and Neck Neoplasms / secondary. Humans. Lymphatic Metastasis / pathology. Middle Aged. Paranasal Sinus Neoplasms / secondary. Scalp / pathology. Skin Neoplasms / secondary. Skull Neoplasms / secondary. Zygoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976707.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


14. Su CW, Lin KL, Hou JW, Jung SM, Zen EC: Spontaneous recovery from a medulloblastoma by a female with Gorlin-Goltz syndrome. Pediatr Neurol; 2003 Mar;28(3):231-4
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gorlin-Goltz syndrome is characterized by nevoid basal cell carcinomas, odontogenic keratocysts of the jaws, palmar and plantar pits, falx calcifications, and various cancer susceptibilities attributed to a mutation in a tumor suppressor gene.
  • She received total excision of the tumor and adjuvant chemotherapy and radiotherapy.
  • One year later, the tumor relapsed with cerebral spinal fluid seeding.
  • She recovered spontaneously with no treatment, and she has not developed basal cell carcinoma within 6 years.
  • Diagnosis of the syndrome should be made as early as possible to avoid aggressive radiotherapy that may induce basal cell carcinomas.
  • [MeSH-major] Basal Cell Nevus Syndrome / diagnosis. Medulloblastoma / diagnosis. Neoplasm Regression, Spontaneous / pathology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12770681.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement